Selecta Wins Allergy Deal with Sanofi Worth up to $900 mln
U.S. vaccine company Selecta Biosciences has signed a deal worth as much as $900 million with French drugmaker Sanofi to develop therapies for
Under the deal, Sanofi will have an exclusive licence to develop a first food allergy therapy, with an option to develop two more, Selecta said in a statement.
Sanofi will have to Selecta’s Synthetic Vaccine Particle platform, which engineers tiny particles that produce tolerance to specific substances that provoke allergies.
“In allergies, as well as
“Our approach addresses the underlying causes of these diseases and thereby makes advances beyond today’s symptomatic treatments and
Selecta said it was entitled to receive payments totalling $300 million for each allergy therapy under the deal with Sanofi, as well as royalties on sales.
Selecta’s pipeline includes vaccines for stopping smoking and malaria, and immunotherapies for